{"entity":{"id":"idea-fund-nonprofit-pharma","kind":"idea","name":"A non-profit pharmaceutical company for the cancers markets ignore","aka":[],"tldr":"Build a drug company that does not need profits, modelled on the ones that developed new tuberculosis and sleeping-sickness drugs, to take on rare, paediatric and undruggable cancers.","summary":"A product development partnership (PDP) for oncology, on the model of the Drugs for Neglected Diseases initiative, TB Alliance and Medicines for Malaria Venture: philanthropic and public core funding, in-licensing of shelved or academic assets, virtual development through contract organisations, trials run with academic networks, and pricing at cost plus a margin reinvested in the pipeline. Target areas are those where the commercial case is weak but the science is ready: paediatric solid tumours, rare fusion-driven cancers, repurposed generics, and de-escalation regimens. The PDP can also be the licensee of last resort for assets that companies abandon.","asOf":"2026-09-08","links":[{"label":"Drugs for Neglected Diseases initiative","url":"https://dndi.org/"},{"label":"TB Alliance","url":"https://www.tballiance.org/"}],"tags":[],"related":["idea-fund-amc-paediatric-rare","idea-fund-shelved-asset-escrow","idea-fund-repurposing-indication-exclusivity"],"cancers":["neuroblastoma","sarcoma","cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-incentive-misalignment","b-rare-cancers","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"An oncology PDP funded at $100 to $200 million a year brings at least three products to registration within a decade in indications with no commercial programme, at development costs under a third of industry averages.","rationale":"DNDi has delivered multiple approved treatments (fexinidazole for sleeping sickness among them) and TB Alliance delivered pretomanid, at a fraction of industry costs, by combining donor funding with in-licensing and academic trial networks. Oncology has large philanthropic flows but no comparable development vehicle.","test":"Seed a PDP with two in-licensed assets and one repurposing programme; success at year five is one asset in a registration trial and a documented cost per phase.","maturity":"speculative","actor":"philanthropy","cost":"large","horizonYears":8},"route":"/ideas/idea-fund-nonprofit-pharma/","neighbours":{"idea":[{"id":"idea-fund-stalled-asset-registry","kind":"idea","name":"A public registry of stalled academic assets and shelved company compounds","route":"/ideas/idea-fund-stalled-asset-registry/"},{"id":"idea-fund-repurposing-indication-exclusivity","kind":"idea","name":"A repurposing label pathway with short exclusivity that non-profits can hold","route":"/ideas/idea-fund-repurposing-indication-exclusivity/"},{"id":"idea-fund-amc-paediatric-rare","kind":"idea","name":"Advance market commitments for paediatric and rare cancer drugs","route":"/ideas/idea-fund-amc-paediatric-rare/"},{"id":"idea-fund-shelved-asset-escrow","kind":"idea","name":"Automatic offer of shelved cancer assets to non-profits after two years","route":"/ideas/idea-fund-shelved-asset-escrow/"},{"id":"idea-fund-milestone-venture-philanthropy","kind":"idea","name":"Milestone-based venture philanthropy with royalties recycled into the pipeline","route":"/ideas/idea-fund-milestone-venture-philanthropy/"},{"id":"idea-fund-open-source-repurposing-leads","kind":"idea","name":"Patent-free open-source development of repurposed and off-patent cancer drugs","route":"/ideas/idea-fund-open-source-repurposing-leads/"},{"id":"idea-fund-national-drug-development-office","kind":"idea","name":"Scale up public drug development that takes academic assets to phase 1","route":"/ideas/idea-fund-national-drug-development-office/"}],"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}]}}